



Myriad Genetics, Inc.
Investor Relations Department
320 Wakara Way
Salt Lake City, UT 84108
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: MYGN

Last Trade:	28.80
Trade Time:	4:00 PM ET Aug 18, 2017
Change:	0.94 (+3.374%)
Day Range	28.26 - 29.01
52-Week Range	15.15 - 29.01
Volume	1,315,637

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patient's lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence.

Why Invest in Myriad Genetics

Myriad's 9 molecular diagnostic tests provide a preeminent market position today; with revenue up 23% in FY2012 our 13 innovative pipeline tests will ensure Myriad's continued growth for the future. Th... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Aug 17, 2017*
[EndoPredict® Receives Positive Coverage Decisions From Medicare and Anthem](#)
- Aug 8, 2017*
[Myriad Genetics Reports Fiscal Fourth-Quarter 2017 and Fiscal Full-Year 2017 Financial Results](#)
- Jul 28, 2017*
[Myriad to Announce Fiscal Fourth-Quarter 2017 Financial Results on August 8, 2017](#)
- Jun 19, 2017*
[Virginia C. Drosos, President of Assurex Health, Receives the EY Entrepreneur of the Year 2017 Award in Ohio Valley Region](#)
- Jun 15, 2017*
[Crescendo Bioscience Announces Results from a Meta-Analysis of Studies with Vectra® DA at the 2017 Annual European Congress of Rheumatology](#)

Financials [\[View all \]](#)

- [Fourth Quarter Financial Results](#)
- Aug 9, 2017*
[Annual Report \(10-K\)](#)
- Oct 11, 2016*
[Proxy Statement \(DEF 14A\)](#)
- May 3, 2017*
[Quarterly Report \(10-Q\)](#)
- Feb 8, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 2, 2016*
[Quarterly Report \(10-Q\)](#)